Annovis Bio's Recent Phase II/III Alzheimer's Study Of Buntanetap, Showed Statistically Significant Efficacy And Safety In Both Carriers And Non-Carriers Of Apolipoprotein E4, A Genetic Cause Of AD
Annovis Bio's Recent Phase II/III Alzheimer's Study Of Buntanetap, Showed Statistically Significant Efficacy And Safety In Both Carriers And Non-Carriers Of Apolipoprotein E4, A Genetic Cause Of AD
Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), today announces that its recent Phase II/III Alzheimer's study of its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a genetic cause of AD.
Annovis Bio Inc.（紐交所：ANVS）（“Annovis”或“公司”）是一家開發神經退行性疾病（如阿爾茨海默病和帕金森病）新療法的後期藥物平台公司，今天宣佈其領先藥物候選Buntanetap的最近進行的第II/III期阿爾茨海默病研究在APOE4攜帶者和非攜帶者中顯示出統計學顯著的療效和安全性。
Interested parties are encouraged to register for the upcoming investor call today at 4:30 PM ET, where detailed findings will be discussed.
鼓勵有興趣的投資者在今天東部時間下午4:30註冊參加即將到來的投資者看漲，屆時將討論詳細的研究結果。
Key Findings:
主要結果：
- Efficacy in Early AD Patients: In patients with early AD (MMSE 21-24), Buntanetap showed a statistically significant dose-response in ADAS-Cog11 scores, with a -3.3 points improvement over baseline and -2.3 points improvement from placebo.
- APOE4 Carriers: In APOE4 carriers treated with 15mg Buntanetap, there was a -3.15 improvement in ADAS-Cog11 scores.
- Comparable Safety: Buntanetap was found to be equally safe in both APOE4 carriers and non-carriers, with no instances of ARIA (Amyloid-Related Imaging Abnormalities).
- Patient Breakdown: The study included 159 APOE4 carriers (33 homozygotes and 126 heterozygotes) and 159 APOE4 non-carriers.
- 早期AD患者的療效：在早期AD患者（MMSE 21-24）中，Buntanetap在ADAS-Cog11評分中顯示出統計學上的劑量反應，基線上下降3.3分和安慰劑下降2.3分。
- APOE4攜帶者：以15毫克的劑量治療APOE4攜帶者的Buntanetap，在ADAS-Cog11評分上下降了3.15分。
- 相似的安全性：Buntanetap在APOE4攜帶者和非攜帶者中均被發現具有相同的安全性，無任何ARIA（與澱粉樣物相關的成像異常）發生。
- 患者分類：該研究包括159例APOE4攜帶者（33例純合子和126例雜合子）和159例APOE4非攜帶者。
譯文內容由第三人軟體翻譯。